Synovics Pharmaceuticals, Inc.
SYVC
$0.00
$0.000.00%
OTC PK
| 07/31/2009 | 04/30/2009 | 01/31/2009 | 10/31/2008 | 07/31/2008 | |
|---|---|---|---|---|---|
| Revenue | -18.48% | 11.70% | 28.69% | 11.26% | 1.09% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -18.48% | 11.70% | 28.69% | 11.26% | 1.09% |
| Cost of Revenue | -9.46% | 9.12% | 13.61% | 0.90% | -3.56% |
| Gross Profit | -38.54% | 17.65% | 68.09% | 38.10% | 13.25% |
| SG&A Expenses | -31.97% | -16.23% | -27.39% | -34.30% | -23.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.29% | -2.65% | -7.02% | -15.77% | -11.82% |
| Operating Income | 17.43% | 51.41% | 80.32% | 76.20% | 43.90% |
| Income Before Tax | 43.35% | 84.99% | 86.08% | 80.79% | 55.96% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 43.35% | 84.99% | 86.08% | 80.79% | 55.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 43.35% | 84.99% | 86.08% | 80.79% | 55.96% |
| EBIT | 17.43% | 51.41% | 80.32% | 76.20% | 43.90% |
| EBITDA | 20.15% | 56.29% | 85.15% | 80.97% | 48.47% |
| EPS Basic | 60.92% | 87.80% | 82.98% | 75.76% | 34.99% |
| Normalized Basic EPS | 67.14% | 68.08% | 64.81% | 55.79% | 3.77% |
| EPS Diluted | 61.01% | 86.78% | 82.07% | 74.84% | 33.92% |
| Normalized Diluted EPS | 65.39% | 72.76% | 68.86% | 59.88% | 8.64% |
| Average Basic Shares Outstanding | 22.33% | 19.29% | 1.60% | -6.30% | -23.22% |
| Average Diluted Shares Outstanding | 5.22% | 35.35% | 16.27% | 7.88% | -10.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |